Idiopathic Parkinsonism Treated with an Extracerebral Decarboxylase Inhibitor in Combination with Levodopa
- 25 September 1971
- Vol. 3 (5777), 729-732
- https://doi.org/10.1136/bmj.3.5777.729
Abstract
The clinical actions of levodopa in Parkinsonism, given with and without an extracerebral decarboxylase in hibitor, L-alpha-methyldopahydrazine, were compared. Twenty-one patients were investigated in a “double-blind cross-over” study, administering levodopa in maximum tolerated dosage. L-Alpha-methyldopahydrazine failed to augment the overall therapeutic actions of levodopa but it consistently alleviated nausea. It is concluded that L-alpha-methyldopahydrazine will prove useful in the management of some Parkinsonian patients who have difficulty in taking levodopa alone.Keywords
This publication has 13 references indexed in Scilit:
- TREATMENT OF PARKINSON'S SYNDROME WITH L-DOPA A DOUBLE BLIND STUDYActa Neurologica Scandinavica, 2009
- L-dopa therapy of Parkinson's disease: plasma L-dopa concentration, therapeutic response, and side effects.1971
- Plasma DOPA response to levodopa administration in man: Effects of a peripheral decarboxylase inhibitorClinical Pharmacology & Therapeutics, 1971
- Blocking the Negative Effects of Pyridoxine on Patients Receiving LevodopaPublished by American Medical Association (AMA) ,1971
- PREVENTION OR REVERSAL OF LEVODOPA-INDUCED CARDIAC ARRHYTHMIAS BY DECARBOXYLASE INHIBITORSThe Lancet, 1970
- False rise in serum uric acid after L-dopa.1969
- Interaction of DOPA Decarboxylase Inhibitors with the Effect of α‐Methyldopa on Blood Pressure and Tissue Monoamines in Rats1Acta Pharmacologica et Toxicologica, 1969
- Modification of Parkinsonism — Chronic Treatment with L-DopaNew England Journal of Medicine, 1969
- Pyridoxine reversal of L-dopa effects in Parkinsonism.1969
- Increase of Cerebral Catecholamines caused by 3,4-Dihydroxyphenylalanine after Inhibition of Peripheral DecarboxylaseNature, 1967